SIMD 2022 Infographic: Advancing the diagnosis and management of a rare neurometabolic disorder: A focus on AADC deficiency
View our infographic, distributed at the PTC Therapeutics symposium at the 2022 SIMD Annual Meeting, which introduces aromatic L-amino acid decarboxylase (AADC) deficiency, describes the key signs and symptoms of the condition, and outlines the tests required for diagnosis
Find out more about the signs and symptoms of AADC deficiency that may raise clinical suspicion and warrant further testing
Learn more about the preliminary tests which may be used to screen for AADC deficiency, and the core diagnostic tests needed to obtain definitive confirmation of the condition
Understand the importance of securing an early and accurate diagnosis for patients with AADC deficiency
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2200063 I July 2022
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.